Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW) "CMB-NOW"

Active, not recruiting

Phase N/A Results N/A

Update History

21 Oct '16
A location was updated in Kawasaki.
New
The overall status was removed for St. Marianna University School of Medicine Hospital.
A location was updated in Sagamihara.
New
The overall status was removed for Kitasato University Hospital.
A location was updated in Yokohama.
New
The overall status was removed for Yokohama City University Hospital.
11 Mar '16
The eligibility criteria were updated.
New
Inclusion Criteria: 1. Diagnosis of NVAF 2. Diagnosis of cerebral infarction or TIA within 2 weeks after onset 3. Patients commenced on NOACs or warfarin therapy as a secondary prevention of cerebral infarction or transient ischemic attack, whether or not anticoagulation therapy was used before enrollment in this study 4. Age ≥20 years and ≤85 years 5. Ability to give valid consent and to provide consent in writing or availability of relatives to provide surrogate consent. 6. At least one CMB detected by 1.5 T MRI (T2*WI) before enrollment in this study Exclusion Criteria: 1. Patients using aspirin or other antiplatelet agents concomitantly 2. Patients in whom NOAC or warfarin is contraindicated 3. Patients with renal dysfunction (CrCL <15 mL/min) 4. Patients with uncontrollable hypertension 5. Patients who are otherwise ineligible to take part in this study as judged by the study doctor
Old
Inclusion Criteria: 1. Diagnosis of NVAF 2. Diagnosis of cerebral infarction or TIA within 2 weeks after onset 3. Patients commenced on NOACs or warfarin therapy as a secondary prevention of cerebral infarction or transient ischemic attack, whether or not anticoagulation therapy was used before enrollment in this study 4. Age ≥20 years and ≤85 years 5. Ability to give valid consent and to provide consent in writing. 6. At least one CMB detected by 1.5 T MRI (T2*WI) before enrollment in this study Exclusion Criteria: 1. Patients using aspirin or other antiplatelet agents concomitantly 2. Patients in whom NOAC or warfarin is contraindicated 3. Patients with renal dysfunction (CrCL <15 mL/min) 4. Patients with uncontrollable hypertension 5. Patients who are otherwise ineligible to take part in this study as judged by the study doctor